MSLE

News

globenewswire.comSatellos Bioscience Announces Results of Annual Meeting of Shareholdersglobenewswire.comJun 17

globenewswire.comSatellos to Participate in Upcoming Investor Conferencesglobenewswire.comMay 27

247wallst.comHere Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More247wallst.comApr 6

Trade MSLE

About Satellos Bioscience Inc. Common Stock

Satellos Bioscience, Inc. is a regenerative medicine firm dedicated to creating novel therapeutic solutions. The company employs its proprietary MyoReGenX™ technology platform, which enables the identification of stem cell regeneration deficits within various muscle diseases and subsequently facilitates the development of targeted treatments. Frank Gleeson and Michael Rudnicki established the company on July 27, 2012, and its corporate headquarters are located in Toronto, Canada.

CEO: Francis Gleeson
IPO Date: May 10, 2024

Market Data

Open: $5.97
High: $5.97
Low: $5.69
Volume: 26.2K
Avg Volume: 48.2K
52W High: $13.40
52W Low: $4.55

Valuation

Market Cap: $7.4M
Enterprise Value: $41M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-24M
Revenue: $0
Net Income: $-25M
Cash: $9.8M
Debt: $0

Events

EarningsAug 12

EPS est. -0.50281